SCHEMBL774702

SCHEMBL774702

O=[N+]([O-])c1ccc2c(O)cccc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.52
ALDH1A1 P00352 2/20 0.52
ALOX15 P16050 1/20 0.52
GPR35 Q9HC97 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
PLAU P00749 1/20 0.50
LMNA P02545 1/20 0.50
TP53 P04637 1/20 0.50
HPGD P15428 1/20 0.50
MAPK1 P28482 1/20 0.50
S100A4 P26447 1/20 0.49
GAA P10253 1/20 0.49
THRB P10828 1/20 0.49
KDM4E B2RXH2 1/20 0.47
NPC1 O15118 1/20 0.47
MAPT P10636 1/20 0.47
PKM P14618 1/20 0.47
NFKB1 P19838 1/20 0.47
HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
P-Nitrophenol SCHEMBL5573898 0.94 ESR1 (0.54) TSHRALDH1A1ALOX15GPR35TDP1
SCHEMBL4958995 0.86 TSHR (0.52) TSHRALDH1A1ALOX15GPR35SMN1; SMN2
Dinitrophenylene SCHEMBL27352655 0.84 LMNA (0.59) TSHRALDH1A1ALOX15TDP1SMN1; SMN2
SCHEMBL28257786 0.81 TSHR (0.54) TSHRALDH1A1ALOX15TDP1LMNA
SCHEMBL8668528 0.80 TSHR (0.66) TSHRALDH1A1GPR35TDP1SMN1; SMN2
SCHEMBL4960980 0.80 TDP1 (0.66) TSHRALDH1A1ALOX15GPR35TDP1
SCHEMBL774010 0.79 CASP6 (0.58) TSHRALDH1A1ALOX15GPR35TDP1
SCHEMBL8686354 0.79 TDP1 (0.52) TSHRALDH1A1ALOX15TDP1LMNA
SCHEMBL14375281 0.79 HSD17B10 (0.53) TSHRALDH1A1TDP1LMNAGAA
SCHEMBL16289713 0.79 TSHR (0.50) TSHRALDH1A1ALOX15TDP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3842076-B1 MULTI-LAYER WOUND CARE PRODUCT WITH PERFORATED RELEASE LAYER BSN MEDICAL GMBH (DE) 2023-02-15 EP claimed
EP-3558399-B1 MULTI-LAYER WOUND CARE PRODUCT WITH PERFORATED RELEASE LAYER BSN MEDICAL GMBH (DE) 2021-01-20 EP claimed
EP-3338813-B1 MULTI-LAYER WOUND CARE PRODUCT WITH PERFORATED RELEASE LAYER BSN MEDICAL GMBH (DE) 2020-01-29 EP claimed
EP-3318532-A1 METHOD AND DEVICE FOR NO INSTILLATION BSN medical GmbH (DE) 2018-05-09 EP claimed
EP-3288893-A1 MULTI-STEP PROCESS FOR NO PRODUCTION BSN Medical Holding GmbH (DE) 2018-03-07 EP claimed
WO-2016174043-A1 MULTI-STEP PROCESS FOR NO PRODUCTION BSN MEDICAL GMBH (DE) 2016-11-03 WO claimed
US-7211414-B2 Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity VISIGEN BIOTECHNOLOGIES, INC. (US) 2007-05-01 US claimed
EP-3415641-B1 METHOD FOR ANALYSIS OF MOLECULES PACIFIC BIOSCIENCES CALIFORNIA INC (US) 2023-11-01 EP disclosed
EP-3534809-B1 DEBRIDEMENT DEVICE BSN MEDICAL GMBH (DE) 2020-09-02 EP disclosed
EP-3458115-B1 WOUND OR SKIN PATCH BSN MEDICAL GMBH (DE) 2020-08-26 EP disclosed
EP-3534809-A1 DEBRIDEMENT DEVICE BSN Medical GmbH (DE) 2019-09-11 EP disclosed
EP-3288517-B1 MEDICAL BATHING DEVICE BSN MEDICAL GMBH (DE) 2019-07-17 EP disclosed
EP-3458115-A1 WOUND DRESSING OR DERMAL PATCH BSN Medical GmbH (DE) 2019-03-27 EP disclosed
US-20060061755-A1 Apparatus and method for analysis of molecules PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 2006-03-23 US disclosed
US-20060061754-A1 Arrays of optical confinements and uses thereof PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 2006-03-23 US disclosed
WO-2004041840-A2 PEPTIDE-BOUND CHROMOGENS USED FOR DETERMINING ENZYMATIC ACTIVITIES C-CIT AG (CH) 2004-05-21 WO disclosed
EP-1354064-A2 ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR ALTERING MONOMER INCORPORATION FIDELITY Visigen Biotechnologies, Inc. (US) 2003-10-22 EP disclosed
US-20030134807-A1 Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity Life Technologies Corporation 2003-07-17 US disclosed
WO-2002044425-A2 ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR ALTERING MONOMER INCORPORATION FIDELITY VISIGEN BIOTECHNOLOGIES, INC. (US) 2002-06-06 WO disclosed
US-6399335-B1 MIXING POLYMERASE AND NUCLEOSIDE TRIPHOSPHATE HAVING A GAMMA PHOSPHATE PHOSPHOESTER-LINKED FUNCTIONAL GROUP, INCUBATING SO THAT POLYMERASE CATALYZES CLEAVAGE BETWEEN ALPHA AND BETA PHOSPHATES AND LIBERATES PYROPHOSPHATE WITH FUNCTIONAL GROUP ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. 2002-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134807-A1 Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity RNGTT, PNP, MTAP TSHR 4361/4885ALDH1A1 1522/4885ALOX15 3324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.